No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
EBS Emergent BioSolutions
- 1.950
- -0.230-10.55%
Close Apr 25 16:00 ET
- 1.990
- +0.040+2.05%
Post 19:52 ET
102.16MMarket Cap-131P/E (TTM)
2.128High1.950Low1.09MVolume2.120Open2.180Pre Close2.18MTurnover2.12%Turnover RatioLossP/E (Static)52.39MShares10.88052wk High0.16P/B100.79MFloat Cap1.42052wk Low--Dividend TTM51.68MShs Float137.610Historical High--Div YieldTTM8.17%Amplitude1.420Historical Low1.996Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise
Amneal Pharmaceuticals (AMRX) rallied Wednesday after the US Food and Drug Administration approved its generic version of the nasal spray used to treat opioid overdose. Amneal's Naloxone HCI nasal spr
FDA Approves Amneal's Generic Version of OTC Narcan
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first
Express News | NYSE Order Imbalance 76629.0 Shares on Buy Side 76629.0 Shares on Buy Side
Institutional Owners May Take Dramatic Actions as Emergent BioSolutions Inc.'s (NYSE:EBS) Recent 16% Drop Adds to One-year Losses
Express News | Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $5 Price Target
Comments
1
$Emergent BioSolutions(EBS.US$ here comes the buying opportunity
still ridiculously undervalued at these levels
happy to buy more and watch the red sale
my most confident stock
still ridiculously undervalued at these levels
happy to buy more and watch the red sale
my most confident stock
3
1
$Emergent BioSolutions(EBS.US$ Emergent BioSolutions Secures Flexible Credit Terms and Guarantor
2
Swing and a miss! Hehehe
$Emergent BioSolutions(EBS.US$ Emergent BioSolutions (NYSE:EBS) reported quarterly losses of $(0.770) per share which missed the analyst consensus estimate of $(0.190) by 305.26 percent. The company reported quarterly sales of $276.600 million which missed the analyst consensus estimate of $293.533 million by 5.77 percent. This is a 16.36 percent decrease over sales of $330.700 million the same period last year.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg